# Yumanity Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yumanity-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.yumanity.com
- Total disclosed funding: $45M
- Latest round: Series A (Feb 8, 2016)
- Investors on record: 6

## About

Yumanity Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases through advanced drug discovery and development technologies.Founded in 2014, Yumanity Therapeutics, Inc. specializes in drug discovery for protein misfolding diseases. The company is headquartered in Boston, US. Richard Peters serves as the CEO. In June 2022, Yumanity engaged in a merger with Kineta, Inc., and Janssen Vaccines & Prevention B.V. agreed to acquire its assets for USD 26 mn, expected to finalize by March 2023.Yumanity offers innovative solutions in drug discovery, focusing on diseases related to protein misfolding, such as neurodegenerative disorders. Utilizing proprietary technology platforms, the company identifies and optimizes novel therapeutic candidates. They employ advanced computational techniques and high-throughput screening to meet unmet medical needs in conditions like Alzheimer’s and Parkinson’s disease, serving biopharmaceutical companies and research institutions across North America and Europe.In 2023, Yumanity reported a revenue of USD 5.44 mn and an EBITDA of USD -13.53 mn, primarily generated through collaborations with pharmaceutical companies that involve milestone payments and royalties linked to therapeutic developments.Yumanity plans to leverage recent funding from the asset acquisition deal to enhance its drug discovery capabilities and expand into new markets by targeting regions in Europe and Asia by 2024. The company is actively working on launching new therapeutic candidates that address critical needs in neurodegenerative disease treatment, with expectations for product introductions as they progress through clinical development phases.

## Funding rounds

- Series A, Feb 8, 2016, $45M — Alexandria Venture Investments, Fidelity Investments, Sanofi Ventures, Biogen Idec New Ventures, Redmile Group, Dolby Family Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A